Renal Denervation Market Size and Share

The renal denervation market was valued at US$ 350.4 million in 2023, and is expected to register a CAGR of 31.2% over the forecast period and reach US$ 4,036.2 million in 2032.

Renal Denervation (RDN), also known as renal ablation, is a minimally-invasive investigational medical procedure to treat hyper tension or high blood pressure in patients who have shown no signs of improvement after being treated with other conventional approaches and treatments. Some known causes of treatment-resistant hypertension include physician inertia, inadequate doses or inappropriate combinations of antihypertensive drugs, poor patient adherence, excess alcohol intake, and volume overload.